Results 301 to 310 of about 369,868 (397)

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

International Journal of Cancer, EarlyView.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze, Salah‐Eddin Al‐Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose, Marina Schaaf, Disorn Sookthai, Bianca Zäpf, Claudia Pauligk, Timursah Habibzade, Ralf‐Dieter Hofheinz, Christine Koch, for the AIO Study Group   +19 more
wiley   +1 more source

Treatment Response of Morphea Patients Referred to a Tertiary Dermatology Hospital: A Three-Year Cohort Study. [PDF]

Health Sci Rep
Kianfar N, Babaahmadi M, Dasdar S, Vahabi SM, Ghiasvand K, Aryanian Z, Ansari MS, Etesami I.   +7 more
europepmc   +1 more source

Improved survival after acute graft-versus-host disease diagnosis in the modern era [PDF]

, 2017
et al.,, Hayashi, Robert J, Vig, Ravi
core   +1 more source

TargetGen‐RNN model discovers novel antibiotic compound targeting drug‐resistant Staphylococcus aureus

Interdisciplinary Medicine, EarlyView.
TargetGen‐recurrent neural network (RNN), an advanced generative model, generated 28,708 unique and novel compounds, identifying SAK‐2970 as a potent antibiotic against drug‐resistant Staphylococcus aureus. Exhibiting strong biofilm inhibition, high therapeutic efficacy, and minimal systemic toxicity in vivo, SAK‐2970 highlights its safety and clinical
Shakeel Ahmad Khan, Adnan Shakoor, Sadia Kanwal   +2 more
wiley   +1 more source

Acute Toxicity and Genotoxicity of cMoL, a Lectin From Moringa oleifera Seeds With Antifungal Activity Against Cryptococcus Strains

Journal of Applied Toxicology, EarlyView.
ABSTRACT Coagulant Moringa oleifera lectin (cMoL) is one of the compounds involved in the application of M. oleifera seeds for traditional water treatment methods. The present study highlights the new biotechnological potential of cMoL lectin as an antifungal agent against Cryptococcus neoformans B3501 and H99 and Cryptococcus gattii R265 strains ...
Matheus Cavalcanti de Barros, Sávia Soraia Santana da Silva, Eduarda Pinto Gagliano, Alícia Natalie Silva dos Santos, Leydianne Leite de Siqueira Patriota, Gustavo Ramos Salles Ferreira, Pollyanna Michelle da Silva, Simone da Paz Leôncio Alves, Julliano Matheus de Lima Maux, Jacinto da Costa Silva Neto, Fernanda Rafaelly Nascimento de Santana, Fabiana Aparecida Cavalcante Silva, Marilene Henning Vainstein, Luana Cassandra Breitenbach Barroso Coelho, Thâmarah de Albuquerque Lima, Thiago Henrique Napoleão, Patrícia Maria Guedes Paiva   +16 more
wiley   +1 more source

Isolated Optic Neuritis as the Presenting Feature of Neurosarcoidosis: A Case Report and Diagnostic Approach. [PDF]

Cureus
Bhalla A, Zubair Z, Hamid U, Kattah J.
europepmc   +1 more source

Is Micronucleus Assay a Suitable Biomarker for Evaluating the Cancer Risk in Professionals Exposed to Antineoplastic Drugs? A Systematic Review

Journal of Applied Toxicology, EarlyView.
ABSTRACT The widespread use of antineoplastic drugs in cancer treatment has led to significant concerns regarding the potential health risks posed to healthcare professionals involved in the preparation, administration, and handling of these chemical compounds, including genotoxicity.
Thiago Guedes Pinto, Lorrany da Silva Avanci, Gabriel Carvalhal de Aguiar, Daniel Vitor de Souza, Patricia Ramos Cury, Ana Claudia Muniz Renno, Daniel Araki Ribeiro   +6 more
wiley   +1 more source

Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Adult Patients With Inflammatory Bowel Disease

The Journal of Clinical Pharmacology, EarlyView.
Abstract Many patients with inflammatory bowel disease (IBD) do not adequately respond to infliximab, potentially due to individual differences in pharmacokinetics (PK). This study aimed to identify clinical and biochemical variables associated with infliximab PK.
Ilse A. Pool, Ilse Volkerink, Mirthe Stavast, Jos G. W. Kosterink, Gerard Dijkstra, Paola Mian, Arno R. Bourgonje   +6 more
wiley   +1 more source

The relationship between urine output and time to methotrexate clearance in pediatric leukemia patients receiving high-dose methotrexate therapy. [PDF]

BMC Cancer
Wang YL, Chang TY, Chen SH, Hsiao YW, Wen YC, Jaing TH.   +5 more
europepmc   +1 more source

Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real-world evidence. [PDF]

J Eur Acad Dermatol Venereol
van der Gang LF, de Bruin-Weller MS.
europepmc   +1 more source